Jpmorgan Chase & CO Adc Therapeutics Sa Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Jpmorgan Chase & CO holds 39,719 shares of ADCT stock, worth $116,773. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,719

Previous 37,021 7.29%

Holding current value

$116,773

Previous $73,000 23.29%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$1.39 - $2.02 $3,750 - $5,449	2,698 Added 7.29%	39,719 $56,000
Q4 2024 Feb 12, 2025	SELL	$1.89 - $3.48 $78,986 - $145,436	-41,792 Reduced 53.03%	37,021 $73,000
Q3 2024 Dec 26, 2024	BUY	$2.59 - $4.01 $126,847 - $196,393	48,976 Added 164.15%	78,813 $248,000
Q3 2024 Nov 08, 2024	BUY	$2.59 - $4.01 $126,847 - $196,393	48,976 Added 164.15%	78,813 $248,000
Q2 2024 Dec 26, 2024	SELL	$2.55 - $5.09 $124,888 - $249,287	-48,976 Reduced 62.14%	29,837 $94,000
Q2 2024 Aug 12, 2024	BUY	$2.55 - $5.09 $76,084 - $151,870	29,837 New	29,837 $94,000
Q2 2023 Aug 11, 2023	SELL	$1.9 - $2.66 $630,292 - $882,409	-331,733 Reduced 10.73%	2,760,081 $5.93 Million
Q1 2023 May 11, 2023	BUY	$1.92 - $5.45 $167,708 - $476,046	87,348 Added 2.91%	3,091,814 $6.03 Million
Q4 2022 Feb 13, 2023	SELL	$2.87 - $5.24 $1.18 Million - $2.16 Million	-412,051 Reduced 12.06%	3,004,466 $11.5 Million
Q3 2022 Nov 14, 2022	SELL	$4.66 - $10.31 $173,142 - $383,068	-37,155 Reduced 1.08%	3,416,517 $16.5 Million
Q2 2022 Aug 11, 2022	BUY	$5.96 - $14.99 $232,690 - $585,239	39,042 Added 1.14%	3,453,672 $27.5 Million
Q1 2022 May 11, 2022	BUY	$13.28 - $20.03 $2.92 Million - $4.4 Million	219,788 Added 6.88%	3,414,630 $50.2 Million
Q4 2021 Feb 10, 2022	SELL	$19.29 - $31.51 $1.41 Million - $2.3 Million	-73,144 Reduced 2.24%	3,194,842 $64.5 Million
Q3 2021 Nov 12, 2021	BUY	$20.45 - $30.0 $66.8 Million - $98 Million	3,267,986 New	3,267,986 $88.8 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

67.5M

Call Options Held

53.7K

Put Options Held

75.8K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $228M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Adc Therapeutics Sa Transaction History